Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.

In later development, statistically significant exacerbation reduction was suggested in the phase 2b ALIENTO trial [ 66 ], whereas the phase 3 ARNASA ( NCT05595642 ) study reported a numerical reduction that did not reach statistical significance, again underscoring variability across studies and the importance of defining the right target population [ 67 ].

also in 111,027 other papers